Remodulin Journal Ad, Booklet Prompt FDA Warning Letter

United Therapeutics' promotional materials make misleading comparisons between Remodulin and GlaxoSmithKline's Flolan, FDA's ad review division says. The company says it discontinued the ads and requested doctors stop using the "Frequently Asked Questions" booklet in July 2004.